Press Room

XGAL-3® Receives FDA Breakthrough Device Designation for the Treatment of Sepsis

Terumo Blood and Cell Technologies collaborates with Eliaz Therapeutics

Eliaz Therapeutics Awarded $1.7 Million by NIH for XGAL3’s Apheresis Large Animal Safety Study